T009 HHSN26100008 TORFP 2018-E03 Prevention of Urinary Bladder Cancer with Two "Clinically-Ready" Agents (Everolimus and Naproxen) when Administered in Combination

Grant

Date/time Interval

  • September 15, 2015 - September 16, 2021
  • Total Award Amount

  • 709567.00
  • Direct Costs

  • 477823.00
  • Sponsor Award Id

  • HHSN261201500036I-75N91018F00008
  • Contributor

  • Grubbs Ph.D., Clinton   Principal Investigator